AstraZeneca Reports Pooled Cardiovascular Safety and Efficacy Analyses of Roxadustat in P-III Program for CKD Patients with Anaemia

 AstraZeneca Reports Pooled Cardiovascular Safety and Efficacy Analyses of Roxadustat in P-III Program for CKD Patients with Anaemia

AstraZeneca Reports Pooled Cardiovascular Safety and Efficacy Analyses of Roxadustat in P-III Program for CKD Patients with Anaemia

Shots:

  • The P-III program involves assessing of Roxadustat vs PBO and epoetin alfa in 9,000+ NDD and DD & ID patients in multiple studies conducted by AstraZeneca, FibroGen and Astellas together globally respectively
  • Results: The risk of MACE, MACE+ and all-cause mortality & Hb level (1.85 g/dL vs 0.13 g/dL) in NDD patients was comparable to PBO, showed 30% lower risk of MACE and 34% lower risk of MACE+ with a trend towards lower all-cause mortality in ID patients, no increased risk of MACE and all-cause mortality and a lower risk of MACE+, Hb level (1.22 g/dL vs 0.99 g/dL) in DD patients
  • Roxadustat is a first-in-class, hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) being evaluated for the treatment of anaemia in CKD. The results from pooled analysis served as a basis for its anticipated regulatory submission in the US in Q4’19

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Barron

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post